Table 3.
Comparison of cervical mucosa radiomics signature in detecting LVSI in early stage cervical cancers
| Characteristic | Primary Cohort (n = 114) | P-value | Validation Cohort (n = 41) | P-value | ||
|---|---|---|---|---|---|---|
| LVSI
(+) (n = 39) |
LVSI
(-) (n = 75) |
LVSI
(+) (n = 13) |
LVSI
(-) (n = 28) |
|||
| Tumor Rad-score (T1CE) | 1.71 ± 1.70 | 1.36 ± 1.23 | 0.23 | 1.80 ± 1.58 | 1.56 ± 1.80 | 0.69 |
| Tumor Rad-score (T2WI) | 1.34 ± 0.94 | 0.96 ± 1.03 | 0.06 | 1.16 ± 0.78 | 1.10 ± 1.39 | 0.88 |
| Tumor Rad-score (Combine) | 2.01 ± 1.53 | 1.33 ± 1.24 | 0.01* | 1.71 ± 0.87 | 1.72 ± 1.14 | 0.98 |
LVSI: Lymph vascular space invasion
P-values were derived from independent-sample T test
T1CE: T1 contrast-enhanced imaging
T2WI: T2 -weighted imaging
*p<0.05